BMW Q1 Roadshow: On Track for Targets; CMD Could Be a Catalyst

Overview

This report captures UBS’s immediate feedback from BMW’s virtual roadshow following its Q1 earnings release. The UBS team spoke with CFO Walter Mertl, Stefan Richmann (Executive VP of Finance & Investor Relations), and Adam Sykes (Head of IR). Overall, BMW delivered a reassuring and confident message. Key takeaways include: the company remains on track to achieve FY26 targets; the late-September CMD (Capital Markets Day) could act as a positive catalyst, laying the groundwork to return to an 8–10% Auto EBIT margin. UBS maintains its Neutral rating with a target price of €88.00, implying 10% upside from the current price of €80.02.

Core views

Regarding FY26 guidance, the CFO expects sequential volume growth—iX3 production ramp-up is imminent, followed by X5 and 7 Series launches in H2. Geographically, strong European sales are compensating for weaker performance in China, supporting overall volume targets. On costs, while 2026 savings are expected to be lower than 2025 levels, combined with modest tariff tailwinds in H2 (e.g., EU imports from the US, USMCA—though the latter carries some uncertainty), the typically H1-heavy EBIT seasonality is expected to normalize in 2026, even with typical Q4 cost pressures. The main margin headwinds stem from higher D&A and reduced R&D capitalization; UBS estimates a net negative FY26 impact of ~€1.3bn, partially offset by lower R&D expenses. The most debated topic was FX/commodity exposure, with the CFO guiding for H2 to be flat year-over-year. On commodity inflation and Middle East risks, BMW is better insulated than peers due to existing contract pricing and hedging. The CFO even suggested that if geopolitical tensions ease, headwinds in 2027 would remain mild. So far, higher oil prices have not negatively impacted demand, and European order books are at record highs. Notably, the iX3 BEV already achieves contribution margins in key European markets on par with ICE X3, meaning accelerating BEV demand won’t drag on profitability. In China, the CFO expects BMW to continue outperforming both peers and the broader market, including year-over-year growth in high-spec models like the X5. Following dealer network restructuring, the business is more resilient; no dealer incentives were paid in Q1, and none are planned for Q2. The locally produced iX3 will launch in November, achieving 'healthy' profitability through cost reductions from Gen6 powertrains and 'competitive' (TBD) pricing. The CFO sees potential to regain share in high-volume segments where BMW previously lacked competitive BEVs, including the upcoming X5 and i3. On CMD and capital allocation, the CFO anticipates the late-September CMD (date TBD) will update the roadmap to return to the 8–10% Auto EBIT margin corridor. New products (including Alpina launches), fixed costs, and product costs are each expected to contribute ~100bps. From an accounting perspective, the end of BBA purchase price allocation (PPA) amortization after Q2/28 will add another ~120bps. Strategic priorities will also cover seamless Neue Klasse rollout (top priority), a preview of the 2030s vision (including autonomy), and the capital allocation framework. The CFO remained vague on the latter, so details are awaited. However, he confirmed no major investment waves are expected beyond Neue Klasse peak, with capex and R&D returning sustainably to strategic corridors in coming years. UBS believes BMW’s €44.8bn (€74/share) net financial asset position is inefficiently allocated, leaving significant upside potential for cash returns (dividends and buybacks).

Analysis framework

This roadshow feedback is based on direct, firsthand communication with management. The analysis follows three core threads: (1) Revenue side—assessing FY26 growth drivers via volume expectations and geographic mix; (2) Margin side—disaggregating annual net impacts of cost items (D&A, R&D, commodities, FX, tariffs) and seasonal patterns; (3) Capital return side—evaluating capital allocation efficiency and cash return potential. For each topic, UBS cross-references management guidance against consensus, historical trends, and peer benchmarks to assess information quality and relative attractiveness.

Methodology notes

• Industry/ Sector Analysis FrameworkVolume-price decomposition

  Decomposing revenue into volume and price components

  In FY26 guidance, the CFO emphasized sequential volume growth and regional mix shifts (strong Europe, weak China)—a classic application of volume-price decomposition. This approach separates revenue growth into volume-driven vs. price-driven components to assess quality and sustainability. Here, volume growth offsets weak China demand, indicating portfolio management—not just price cuts—is supporting revenue.

• Company Fundamentals & Financial FrameworkFree cash flow analysis

  Assessing cash generation and capital efficiency via changes in capex, R&D, and operating cash flow

  BMW expects FY26 capex and R&D to return to strategic corridors, implying improved free cash flow and higher cash returns. Within this framework, UBS notes the €44.8bn net financial asset position is inefficient relative to market cap, indicating ample room to convert earnings into shareholder returns.

• Industry/ Sector Analysis FrameworkSupply-demand framework

  Analyzing competitive positioning via asymmetric supply-side capacity rollouts and demand-side regional performance

  Statements like 'strong Europe, weak China' and the localized iX3 ramp-up to address BEV demand upgrades exemplify this framework—focusing on when/where supply capacity is added versus regional demand strength and product penetration. BMW balances uneven global demand through regional mix and product innovation.

• Valuation MethodologySOTP (Sum-of-the-Parts) Valuation

  Building separate EV/EBIT multiple models by business segment/product line, then aggregating to derive total target price

  The report explicitly states the PT is based on an SOTP model (applying target EV/EBIT multiples to each segment) plus an average target PE. This allows UBS to differentiate profitability and risk premiums across businesses.

• Cyclical & Sentiment FrameworkInflection Point Analysis

  Using leading indicators like order books, inventory, and pricing power to identify cyclical bottoms and recoveries

  The CFO’s mention of record-high European order books is a key leading signal of an upward inflection. Combined with no dealer incentives in China post-restructuring, BEVs reaching profitability, and ongoing cost savings, this points to a recovery path from trough levels.

• Company Fundamentals & Financial FrameworkROIC–WACC spread

  The difference between Return on Invested Capital (ROIC) and Weighted Average Cost of Capital (WACC), measuring value creation for shareholders

  Forecasts show ROIC rising from 16.5% in FY26 to 27.7% in FY30, creating a significant positive spread over WACC in a low-rate environment, supporting enhanced value creation and capital return capacity.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• BMW (BMWG.DE)

  Roadshow subject; CFO’s business and financial outlook directly underpins valuation and share price performance

  Strengths

  Record-high European order books; improved cost competitiveness of localized BEVs; exit from dealer incentives reflects stronger China resilience; emerging cost and efficiency advantages from Neue Klasse architecture; strong cash position supports return potential

  Weaknesses

  China demand remains relatively weak, structurally optimized but still an absolute drag; FY26 margin further declines to 6.3% (trough), creating near-term pressure; capex (Neue Klasse investment) remains elevated through FY26–FY28, limiting free cash flow; BEV profitability has just reached breakeven, carrying execution risk

  Risks

  Slower-than-expected China demand recovery; international trade friction (tariffs, FX moves) exceeding CFO’s 'mild' outlook; Neue Klasse ramp delays or yield issues; BEV sales mix or ASP falling short of profit targets; macro rate shifts impacting financing costs and consumer demand; intensifying competition (especially from Chinese OEMs and tech firms)

Key data

• December Target Price€88.00Based on SOTP model and average target PE; implies 9.98% upside from current price of €80.02
• Current Price€80.02As of May 12, 2026
• FY26 EBIT Margin6.3%Down from 7.6% in FY25 and 8.1% in FY24; primarily pressured by higher D&A and lower R&D capitalization
• Estimated Net FY26 EBIT HeadwindApprox. €1.3bnFrom higher D&A and lower R&D capitalization, partially offset by reduced R&D expenses
• FY26–FY30 EBIT Margin Recovery Path6.3% → 7.3% → 8.0% → 9.0% → 9.2%CMD expected to show ~100bps each from new products and costs, plus ~120bps from BBA amortization ending
• Net Financial Asset Position€44.8bn (€74/share)UBS views this as inefficiently allocated relative to market cap and cash generation capacity
• No Dealer Incentives Expected in Q1/FY26—Indicates improved resilience in China; no support planned for Q2 either
• Local iX3 Launch TimingNovember 2026Expected to achieve healthy profitability and competitive pricing via cost reductions
• CMD Update TimingLate September 2026Expected to detail the roadmap back to 8–10% Auto EBIT margins and capital allocation framework

Impact & implications

The roadshow signals BMW is transitioning from a trough toward recovery across multiple dimensions. First, robust volume outlook (Europe offsetting China weakness), sustained cost savings (albeit at a slower pace than last year), and controlled commodity/FX drag support the company’s ability to meet FY26 guidance. Second, the upcoming localized iX3 and achieved BEV profitability unlock new growth in China, particularly in regaining share in high-volume segments. Third, Neue Klasse’s breakthroughs in cost, quality, and production efficiency—combined with the exit from dealer incentives—will gradually restore margins, with EBIT expected to recover from a 6.3% trough in FY26 to above 9% by FY30, approaching the 8–10% target corridor. Fourth, strong cash generation and a €44.8bn net financial asset position provide ample room for enhanced shareholder returns. The September CMD will be a critical moment to validate and reinforce this narrative, potentially delivering a detailed multi-year margin recovery plan, new product contributions, and capital allocation strategy—creating meaningful upside catalysts. Overall, BMW’s transition from a stress phase to a recovery phase is taking shape.

Risks

• China demand recovery falls short of CFO expectations, pressuring pricing and volumes
• Neue Klasse capacity ramp delayed or costs exceed expectations, slowing margin recovery
• Commodity and FX volatility exceeds hedge coverage, eroding cost savings
• BEV penetration or ASP below expectations, missing profitability targets
• Trade policy shifts (tariffs, localization rules) increase supply chain costs
• September CMD market reaction underwhelms, limiting catalytic effect

What to watch

• Detailed breakdown at late-September CMD of the 8–10% EBIT margin roadmap and Neue Klasse contributions
• Q2 and H2 volume data and regional mix shifts (China relative performance, localized BEV orders)
• Local iX3 pricing and market reception (order conversion and margin realization post-November launch)
• Dealer incentive dynamics and China competitive landscape evolution through the year
• Neue Klasse ramp progress, yield rates, and cost savings realization
• Actual FX and commodity volatility vs. CFO’s 'flat' H2 guidance